1. An Introduction to NRG Oncology
Angeles Alvarez Secord, MD, MHSc
NRG Oncology Semi-Annual Meeting
Phoenix Arizona
February 8, 2019

2. Disclosures Clinical Trial Grants Advisory Boards
AbbVie, Amgen, Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim, BMS, Eisai, Endocyte, Exelixis, Incyte, Merck, PharmaMar, Prima, Biomed, Roche/Genentech, TapImmune and TESARO.
Advisory Boards
Alexion, Aravive, Astex, AstraZeneca, Clovis, Janssen/Johnson & Johnson, Merck, Mersana, Myriad, Oncoquest, Roche/Genentechand TESARO 

3. Objectives
1. Define the different processes within NRG Oncology at each phase in the lifespan of a clinical trial. 
2. Utilize the NCI Cancer Therapy Evaluation Program (CTEP) Project Team Member Applications (PTMA) 
3. To develop a strategy to use NRG Oncology study data for ancillary projects 

4. Agenda
Nancy Soto, Director - NRG Oncology Protocol Development Process 
Mike Sill, PhD - The Role of the Statistician in Protocol Development and Study Design 
Carol Aghajanian, MD – Project Team Member Applications: Understanding PTMA 
Steven Waggoner, MD – NRG Oncology Study Data for Ancillary Projects 
** Please remember to complete your evaluations**